Amprion and MLM Therapeutics expanded the availability of a key prostate alpha-synuclein diagnostic by licensing the seed amplification assay technology behind Amprion’s SAAmplify-αSYN test to MLM. The collaboration targets European drug trials by improving access to the assay. In advanced cancer diagnostics, NeoGenomics pushed further into NGS-based MRD and therapy selection with the launch of PanTracer Pro and RaDar ST, aiming to differentiate through menu breadth across community oncology. Investor reception has been supportive, with the company’s shares more than doubling over the prior year. For liver cancer, researchers highlighted the mechanistic basis for HCC spread tied to LINC02709, describing increased stemness and reduced Kupffer cell phagocytosis—an example of how molecular biology findings are tightening links to actionable biomarkers and target hypotheses.